All News | RheumNow

All News

ANCA, vasculitis, test

Best of 2022: ACR/EULAR 2022 Classification Criteria for Granulomatosis with Polyangiitis

Save

d Jack Cush, MD

Dec 20, 2022

The ACR/EULAR 2022 revised classification criteria for granulomatosis with polyangiitis (GPA) have been updated with performance characteristics and are validated for use in clinical research.

Read Article

knee.surg2_.jpg (keep)

Metformin Reduces Osteoarthritis Risk in NIDDM Patients

Save

d EurekAlert!

Dec 19, 2022

Osteoarthritis is a common chronic condition that usually causes joint pain and can be severe enough to require knee and hip replacements.

Read Article

Lungs ILD

Best of 2022: Approach to ILD in Myositis Syndromes

Save

d Jack Cush, MD

Dec 19, 2022

Mehta et al have published a full read review of managing interstitial lung disease (ILD) in patients with inflammatory myopathies, a heterogeneous group of syndromes connected by ILD and and increased morbidity and mortality risk.

Read Article

Leflunomide versus azathioprine in lupus nephritis? Study of 215 bx proven LN given either LEF or AZA - Renal flares were equal (15.7% v 17.8%), as was time to flare (16 mo vs AZA 14 mo); 24-hr proteinuria, creatinine, C3 and C4 improved similarly. https://t.co/fbzhuFT3lh

Links:

https://bit.ly/3PDEsaQ

Dr. John Cush RheumNow ( View Tweet)

Dec 20, 2022

From the Hopkins Lupus cohort - Just one month of Prednisone 40 mg/d yields a FOUR fold increase in avascular necrosis risk #UTSWSLE2022 https://t.co/Kae2PMVgl7 https://t.co/XuhbkBwlCw

Links:

https://bit.ly/3hzhBRo

Dr. John Cush RheumNow ( View Tweet)

Dec 20, 2022

MTX side effects more prominent in PsA than RA pts. Study of 240 PsA & 86108 RA pts starting either MTX or TNFi. TNFi AE same betw PsA & RA, but MTX adverse greater in PsA (44.8% vs. 29.4%), especially N/V, abdominal pain, depression, tinnitus https://t.co/qpGYDguYBK https://t.co/KUNQrSBNO2

Links:

https://bit.ly/3v4PoVI

Dr. John Cush RheumNow ( View Tweet)

Dec 20, 2022

Cancer Risk with Scleroderma Spanish Scleroderma Registry examined a large cohort of systemic sclerosis (SSc) patients showing an increased cancer risk, especially breast, lung, hematologic and colorectal cancer. https://t.co/S3EHajMF9q #BestOf2022 https://t.co/kV772Jef4V

Links:

https://bit.ly/3WwbOus

Dr. John Cush RheumNow ( View Tweet)

Dec 20, 2022

#BestOf2022 Metanalysis of 7 studies shows that oral anticoagulants need not be discontinued for joint injections or aspiration. Only pts w/ hemorrhage after 5427 procedures, over 32-yrs. INR values of 3 bleeding cases was 1.9, 2.3, and 3.4. https://t.co/8e1zIhDTJt https://t.co/L4vIkWf2OL

Links:

https://bit.ly/3V8L9D1

Dr. John Cush RheumNow ( View Tweet)

Dec 20, 2022

#BestOf2022 Co-administration of MTX with Folic Acid on the same day did not reduce efficacy compared to FA application one day after MTX. (based on AIA was induced in female Lewis rats) https://t.co/uh78ZdsqgP https://t.co/j32q68DU0X

Links:

https://bit.ly/3VaD40o

Dr. John Cush RheumNow ( View Tweet)

Dec 19, 2022

COVID-19 Vaccine Responses in Rheumatic Disease Patients Nature Reviews Rheumatology features a review of three notable papers that address the impact of SARS-CoV-2 vaccination on people with inflammatory rheumatic disease. https://t.co/R9UM3amPRR. https://t.co/WmHyVKdsxw

Links:

https://bit.ly/3BKdCYP

Dr. John Cush RheumNow ( View Tweet)

Dec 19, 2022

JAK Inhibitor Potential in Systemic Sclerosis-Associated ILD The occurrence of interstitial lung disease (ILD) in Systemic sclerosis portends serious morbid and mortal outcomes for those affected. https://t.co/I1TCG3AtaW https://t.co/T7r2VKBPhG

Links:

https://bit.ly/3BNd4l1

Dr. John Cush RheumNow ( View Tweet)

Dec 19, 2022

New download available-GCA and PMR New Drugs https://t.co/m6ELSOLd4z. https://t.co/8a52dQ9wSk

Links:

https://bit.ly/3Wp18Oq

Dr. John Cush RheumNow ( View Tweet)

Dec 19, 2022

Low dose steroids can negatively impact bone health Dr. Janet Pope discusses abstract L01 presented at ACR22. https://t.co/IbwnvCPszh https://t.co/bpswN5plNi

Links:

https://bit.ly/3WnQsiU

Dr. John Cush RheumNow ( View Tweet)

Dec 19, 2022

The First Head to Head trial in Axial SpA Dr.Gensler discusses abstract L15 presented at #ACR22. L15: Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic AxSpA: A Randomized Phase IIIb Study https://t.co/J0DT1yw0vQ https://t.co/kKhFQKAy6H

Links:

https://bit.ly/3BKdqZB

Dr. John Cush RheumNow ( View Tweet)

Dec 18, 2022

Practical Guidance for the Clinical Rheumatologist in Unplanned Pregnancies Women of reproductive age comprise an overwhelming majority of patients with rheumatic and musculoskeletal disease. https://t.co/x44GTLRtnT https://t.co/YlLgqeDRgP

Links:

https://bit.ly/3Wp169g

Dr. John Cush RheumNow ( View Tweet)

Dec 18, 2022

2022 ACR/EULAR Giant Cell Arteritis Classification Criteria Giant cell arteritis (GCA) has historically been a clinical diagnosis (visual loss, headache, jaw pain, scalp tenderness, etc) supported by labs and histopathology. https://t.co/DN82rXco3N https://t.co/dpIixCFseT

Links:

https://bit.ly/3j6CDad

Dr. John Cush RheumNow ( View Tweet)

Dec 18, 2022

73-87% of autoimmune (RA, SLE, UCTD, APL) pts used HCQ during pregnancy. HCQ significantly reduced pre-eclampsia (20% vs 9%), early-onset pre-eclampsia (8% vs 2.5%), 2nd/3rd trimester pregnancy loss (3% vs. 0.6%) https://t.co/CF5ivHeCmY https://t.co/CYqaCCuZJz

Links:

https://bit.ly/3hFU6pz

Dr. John Cush RheumNow ( View Tweet)

Dec 18, 2022

Fever, FROST, & Pericarditis Dr. Jack Frost reviews the news, and journal articles from the past week on RheumNow and ends with an audience question on "Macro-CK. https://t.co/IFxocGkOxJ https://t.co/OzoS248ZRK

Links:

https://bit.ly/3uXlRx9

Dr. John Cush RheumNow ( View Tweet)

Dec 17, 2022

Review of the Rheumatic causes of Pericarditis and their management. Causes: SLE, RA, MCTD, Myositis, EGPA, GPA, IgG4-rel Dz, FMF, TRAPS, CAPS, AOSD, JIA, Sarcoidosis, Kawasakis, GCA, Takayasu's https://t.co/MQmkUe4Yey https://t.co/FSfrznoeBe

Links:

Dr. John Cush RheumNow ( View Tweet)

Dec 17, 2022

JAK Inhibitor Potential in Systemic Sclerosis-Associated ILD The occurrence of interstitial lung disease (ILD) in Systemic sclerosis portends serious morbid and mortal outcomes for those affected. https://t.co/LWHKO0gRu4 https://t.co/i2IOLcAgt3

Links:

https://bit.ly/3FUz6oy

Dr. John Cush RheumNow ( View Tweet)

Dec 16, 2022

×